Amgen Inc. (NASDAQ:AMGN) is Weaver C. Barksdale & Associates Inc.’s 9th Largest Position

Weaver C. Barksdale & Associates Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,215 shares of the medical research company’s stock after selling 120 shares during the period. Amgen makes up about 2.1% of Weaver C. Barksdale & Associates Inc.’s holdings, making the stock its 9th biggest position. Weaver C. Barksdale & Associates Inc.’s holdings in Amgen were worth $2,254,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. TCW Group Inc. boosted its holdings in shares of Amgen by 25.1% during the fourth quarter. TCW Group Inc. now owns 174,891 shares of the medical research company’s stock worth $50,376,000 after purchasing an additional 35,040 shares during the period. Grassi Investment Management purchased a new stake in shares of Amgen during the 1st quarter valued at about $2,283,000. Public Employees Retirement System of Ohio grew its position in Amgen by 1.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 281,791 shares of the medical research company’s stock worth $81,161,000 after purchasing an additional 4,376 shares during the period. Meyer Handelman Co. boosted its position in Amgen by 7.2% in the second quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after purchasing an additional 8,700 shares during the last quarter. Finally, Chicago Partners Investment Group LLC boosted its holdings in shares of Amgen by 1.3% in the fourth quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock worth $1,388,000 after buying an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AMGN shares. Royal Bank of Canada lifted their price objective on Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. TD Cowen boosted their price target on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Argus lifted their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Bank of America increased their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Eleven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $327.28.

Amgen Trading Up 0.9 %

Shares of Amgen stock opened at $335.95 on Friday. The company’s fifty day moving average is $329.44 and its two-hundred day moving average is $305.22. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The company has a market capitalization of $180.22 billion, a P/E ratio of 47.99, a PEG ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same period in the prior year, the company earned $5.00 earnings per share. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. Analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.